IMPROVING TREATMENT OPTIONS IN POLYCYTHEMIA VERA: FROM INTERFERON TO NEW AGENTS
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by the overproduction of red blood cells, often accompanied by increased white blood cells and platelets. The disease is primarily driven by mutations in the Janus kinase 2 (JAK2) gene, specifically the JAK2 V617F mutation...
Saved in:
| Main Author: | Can Özlü |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924029584 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alfa
by: Milena Kalmer, et al.
Published: (2025-04-01) -
Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
by: Stine Ulrik Mikkelsen, et al.
Published: (2018-08-01) -
OCT angiography in polycythemia vera
by: Pradeep K Panigrahi
Published: (2025-06-01) -
Polycythemia Vera: New Diagnostic Concept and Its Types
by: AM Kovrigina, et al.
Published: (2016-04-01) -
Takotsubo Cardiomyopathy Associated with Polycythemia Vera
by: Sijan Basnet, et al.
Published: (2018-01-01)